DATE: October 17, 2017TIME: 08:00am PDT, 11:00am EDTResearching and understanding the mechanisms of drug resistance are essential to determine therapies that are more effective on an in...
Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of only 9%. Acquired drug resistance is a major factor that limits the effectiveness of chemotherapy. Exosomes, secreted...
We developed two computational methods, CARE and TIDE, to predict response and resistance to targeted therapies and immunotherapies. CARE infers gene signatures of targeted therapy response b...
Pancreatic cancer is one of the “deadly” cancers, defined as those with a 5-year relative survival rate of less than 50%. Although ranking 12th in terms of incidence, it is...
DATE: October 10, 2017TIME: 9:00AM PDTPatient-derived xenografts (PDX) are increasingly being used in biomedical research for therapeutic analysis in mice. Unlike traditional cell line...
DATE: September 28, 2017TIME: 10:00am PDT, 1:00pm EDT The use of gene therapy is well studied due to its potential to treat cancer, the second leading cause of death worldwide....
The global threat of antimicrobial resistance has been recognized by the World Health Organization, the United Nations and many other expert bodies. The burden of resistant pathogens is immen...
Increasing prevalence and severity of multi-drug-resistant (MDR) bacterial infections has necessitated novel antibacterial strategies. Ideally, new approaches would target bacterial pat...
Adjunct probiotic therapy has the potential to decrease Clostridium difficile disease incidence and severity. After screening several potential probiotic bacteria for intrinsic resistance to...
DATE: September 7, 2017TIME: 9:00AM PT, 12:00PM ETThe success of immune checkpoint blockade adds a new therapeutic category to the cancer therapy repertoire. Despite efforts made on can...
DATE: August 30, 2017TIME: 10:00am PT, 1:00pm ETRecent studies show that cancer cells can resist treatment by changing into a different cell type. Many treatments for specific cancers,...
Creating inducible Pluripotent Stem Cell (iPSC) collections of rare patients scattered world-wide can lower the barrier of biological discovery of rare disease, provide a platform for potenti...
EVENT DETAILS:DATE: July 25, 2017TIME: 9:00am PT, Noon ETThermo Fisher Scientific is proud to present the SyncD3 webinar series. As a thought-leader in science...
DATE: July 20, 2017TIME: 8:00am PT, 11:00am ET, 5:00pm CESTNeurodevelopmental disorders (NDDs) are clinically and etiologically highly heterogeneous and are characterized by a...
Human pluripotent stem cells (hPSCs) and their derivatives are increasingly being used in industry to gain a competitive edge in drug discovery and a new wave of biotechnology start-up compan...
Therapeutic application of pluripotent stem (PS) cell-derived products represents the ultimate goal of stem cell research. In order to apply this technology to patients, it is fundamental to ...
The emergence of technology for development of induced pluripotent stem cells (iPSCs) from somatic cells, such as skin and blood cells, has resulted in the ability of researchers to have limi...
DATE: June 8, 2017TIME: 10:00AM PDT, 1:00PM EDT, 7:00PM CESTAlzheimer’s Disease (AD) is the result of complex interactions between risk factors that cause pleiotropic changes in m...
Open Targets is a public-private partnership made up of four global leading institutions in the fields of pharmaceuticals, bioinformatics and genomics, GSK, EMBL-EBI, the Wellcome Trust Sange...
EVENT DETAILS:DATE: May 16, 2017TIME: 9:00am PT, Noon ETThermo Fisher Scientific is proud to present the SyncD3 webinar series. As a thought-leader in science our first commit...
The realization of the promise of personalized molecular medicine requires efficient development and implementation of novel targeted therapeutics linked to molecular markers able to identify...
DATE: May 9th, 2017TIME: 10:00AM PDT, 1:00PM ETMyeloproliferative neoplasms including myelofibrosis (MF) are characterized by anemia, splenomegaly, bone marrow fibrosis and inflammatory...
DATE: May 2, 2017TIME: 8:00am PT, 11:00am ET, 4:00pm GMT, 5:00pm CETThe natural immune responses that patients develop to their own tumors, as well as therapeutic regimens employin...
DATE: October 17, 2017TIME: 08:00am PDT, 11:00am EDTResearching and understanding the mechanisms of drug resistance are essential to determine therapies that are more effective on an in...
Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of only 9%. Acquired drug resistance is a major factor that limits the effectiveness of chemotherapy. Exosomes, secreted...
We developed two computational methods, CARE and TIDE, to predict response and resistance to targeted therapies and immunotherapies. CARE infers gene signatures of targeted therapy response b...
Pancreatic cancer is one of the “deadly” cancers, defined as those with a 5-year relative survival rate of less than 50%. Although ranking 12th in terms of incidence, it is...
DATE: October 10, 2017TIME: 9:00AM PDTPatient-derived xenografts (PDX) are increasingly being used in biomedical research for therapeutic analysis in mice. Unlike traditional cell line...
DATE: September 28, 2017TIME: 10:00am PDT, 1:00pm EDT The use of gene therapy is well studied due to its potential to treat cancer, the second leading cause of death worldwide....
The global threat of antimicrobial resistance has been recognized by the World Health Organization, the United Nations and many other expert bodies. The burden of resistant pathogens is immen...
Increasing prevalence and severity of multi-drug-resistant (MDR) bacterial infections has necessitated novel antibacterial strategies. Ideally, new approaches would target bacterial pat...
Adjunct probiotic therapy has the potential to decrease Clostridium difficile disease incidence and severity. After screening several potential probiotic bacteria for intrinsic resistance to...
DATE: September 7, 2017TIME: 9:00AM PT, 12:00PM ETThe success of immune checkpoint blockade adds a new therapeutic category to the cancer therapy repertoire. Despite efforts made on can...
DATE: August 30, 2017TIME: 10:00am PT, 1:00pm ETRecent studies show that cancer cells can resist treatment by changing into a different cell type. Many treatments for specific cancers,...
Creating inducible Pluripotent Stem Cell (iPSC) collections of rare patients scattered world-wide can lower the barrier of biological discovery of rare disease, provide a platform for potenti...
EVENT DETAILS:DATE: July 25, 2017TIME: 9:00am PT, Noon ETThermo Fisher Scientific is proud to present the SyncD3 webinar series. As a thought-leader in science...
DATE: July 20, 2017TIME: 8:00am PT, 11:00am ET, 5:00pm CESTNeurodevelopmental disorders (NDDs) are clinically and etiologically highly heterogeneous and are characterized by a...
Human pluripotent stem cells (hPSCs) and their derivatives are increasingly being used in industry to gain a competitive edge in drug discovery and a new wave of biotechnology start-up compan...
Therapeutic application of pluripotent stem (PS) cell-derived products represents the ultimate goal of stem cell research. In order to apply this technology to patients, it is fundamental to ...
The emergence of technology for development of induced pluripotent stem cells (iPSCs) from somatic cells, such as skin and blood cells, has resulted in the ability of researchers to have limi...
DATE: June 8, 2017TIME: 10:00AM PDT, 1:00PM EDT, 7:00PM CESTAlzheimer’s Disease (AD) is the result of complex interactions between risk factors that cause pleiotropic changes in m...
Open Targets is a public-private partnership made up of four global leading institutions in the fields of pharmaceuticals, bioinformatics and genomics, GSK, EMBL-EBI, the Wellcome Trust Sange...
EVENT DETAILS:DATE: May 16, 2017TIME: 9:00am PT, Noon ETThermo Fisher Scientific is proud to present the SyncD3 webinar series. As a thought-leader in science our first commit...
The realization of the promise of personalized molecular medicine requires efficient development and implementation of novel targeted therapeutics linked to molecular markers able to identify...
DATE: May 9th, 2017TIME: 10:00AM PDT, 1:00PM ETMyeloproliferative neoplasms including myelofibrosis (MF) are characterized by anemia, splenomegaly, bone marrow fibrosis and inflammatory...
DATE: May 2, 2017TIME: 8:00am PT, 11:00am ET, 4:00pm GMT, 5:00pm CETThe natural immune responses that patients develop to their own tumors, as well as therapeutic regimens employin...
Follow
